Independent. Not owned by or funded by any pharmaceutical manufacturer.
Evidence-sourced · medically-reviewed where indicated
Side effects

Does GLP-1 cause hair loss?

Evidence-sourced
Written and fact-checked to our published editorial standards.Last updated 2026-07-24. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

The short answer

Usually indirectly, yes — but the medication is not attacking your hair. Shedding during GLP-1 treatment is almost always telogen effluvium: a temporary reaction to rapid weight loss and reduced calorie intake, the same response seen after childbirth, major surgery, severe illness, or crash dieting.

It typically starts two to three months after the trigger, and hair generally regrows once weight and nutrition stabilise. It is not usually permanent, and it is not usually a reason to stop treatment — though it is worth a conversation with your doctor, because other treatable causes look identical.

What telogen effluvium actually is

Your hair follicles cycle between a growing phase and a resting phase. At any moment most follicles are growing. A significant physical stressor can push an unusually large share of them into the resting phase at once. Those hairs stay put for a couple of months, then shed together — which is why the shedding appears well after the event that caused it.

The characteristic experience is diffuse thinning across the whole scalp, and noticeably more hair in the shower drain, on the pillow, or in your brush. It does not usually produce bald patches or a receding hairline — those patterns point to different conditions worth getting checked.

Why GLP-1 treatment triggers it

The trigger is generally the weight loss itself, not a direct drug effect on hair:

This is why hair shedding is also well documented after bariatric surgery and other rapid weight-loss interventions — it tracks the weight loss, not the specific method.

What the label actually reports

Hair loss does appear in the Wegovy prescribing information as a reported adverse reaction, and the reported rate rises with dose:

Hair loss reported in trials of Wegovy (semaglutide) in adults, by percentage of participants. Source: FDA prescribing information.
GroupReported hair loss
Placebo1%
Wegovy 2.4 mg weekly3%
Wegovy 7.2 mg weekly6%

Two things follow from those numbers. Hair loss is not one of the common side effects — at the standard 2.4 mg dose it was reported by roughly 3 in 100 people, against 1 in 100 on placebo. But the rate doubles again at the higher dose, which fits the pattern you would expect if the driver is the speed and scale of weight loss rather than a direct drug effect on the follicle.

What typically happens, and when

What actually helps

Talk to a doctor if

  • You have distinct bald patches, rather than diffuse thinning.
  • Shedding continues well beyond six months, or worsens after weight stabilises.
  • You also have fatigue, cold intolerance, or other symptoms suggesting thyroid disease or anaemia.
  • There is scalp pain, scaling, redness, or scarring.
  • It is affecting your wellbeing — that alone is a legitimate reason to seek help.

Should you stop the medication?

That is a decision for you and your prescriber, but hair shedding of this type is generally self-limiting and not a sign of harm, while the conditions being treated carry real risks of their own. Do not stop a prescribed medication on your own — raise it with your prescriber, who can also check for the treatable causes above. For related background, see how GLP-1 medications work and our full side-effect overview.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

  1. StatPearls clinical referenceNCBI Bookshelf, U.S. National Library of MedicineSupports: Telogen effluvium: triggers, typical 2–3 month delay, and expected recovery.
  2. FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: Whether alopecia appears as a reported adverse reaction in each product's label.
  3. Patient drug and condition informationMedlinePlus, U.S. National Library of MedicineSupports: Patient-level background on hair-shedding causes and nutritional deficiency.
  4. Diabetes, obesity and digestive-disease informationNational Institute of Diabetes and Digestive and Kidney Diseases (NIH)Supports: Rapid weight loss and nutritional considerations during obesity treatment.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.